YD Bio and EG BioMed Launch Telehealth Platform Covering 44 States, D.C. and Guam
YD Bio and EG BioMed launched the EG Telehealth Platform across 44 U.S. states, Washington D.C., and Guam, supported by a nationwide network of licensed physicians. The digital infrastructure enables scalable deployment of multi-cancer detection and decentralized diagnostic services without expanding physical facilities.
1. Launch of EG Telehealth Platform
YD Bio and EG BioMed officially launched the EG Telehealth Platform, providing digital cancer detection and clinical service delivery infrastructure now live across 44 states plus Washington D.C. and Guam. The multi-state platform is supported by a network of licensed physicians and a CLIA/CAP-certified laboratory.
2. Scalable, Asset-Light Model
The platform’s digital architecture reduces reliance on physical infrastructure, enabling rapid scaling of diagnostic services and future clinical trial support with minimal incremental spending. It integrates patient access, sample collection, and connectivity with clinical and research workflows.
3. Multi-Cancer Detection Capabilities
The EG Telehealth Platform supports screening and monitoring for pancreatic, colorectal, liver, gastrointestinal, and breast cancers, addressing high-demand areas of unmet clinical need. The integrated ecosystem combines YD Bio’s methylation-based testing programs with EG BioMed’s diagnostic expertise.
4. Merger and Future Outlook
YD Bio signed a memorandum of understanding to merge with EG BioMed in January 2026, with the transaction expected to close later in 2026 subject to regulatory approvals and definitive agreements. This partnership aims to strengthen YD Bio’s commercialization strategy and expand its diagnostic offerings.